Ovid Therapeutics Inc. (OVID) Dividend History

Company News

• Ovid Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference

  Ovid Therapeutics, a biopharmaceutical company focused on brain conditions, announced that its President and COO will present at the upcoming TD Cowen conference. The company is advancing a pipeline of novel small molecule candidates for neurological and neuropsychiatric disorders.

  GlobeNewswire Inc.
• Epilepsy Market Assessment in the 7MM by 2034 — A Detailed Analysis of Growth Prospects Across Different Types | DelveInsight

  The epilepsy market is expected to grow due to an increase in disease prevalence and the launch of emerging therapies. The market is segmented into partial epilepsy, chronic focal epilepsy, and drug-resistant epilepsy, with various treatment options and pipeline drugs.

  GlobeNewswire Inc.

  Featured Companies: XENE
• Ovid Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

  Ovid Therapeutics, a biopharmaceutical company focused on brain conditions, announced that it will participate in a virtual presentation at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 12, 2025.

  GlobeNewswire Inc.
• Ovid Therapeutics and Graviton Bioscience Announce Topline Data from a Phase 1 Clinical Trial Studying OV888/GV101 Capsule, a Potential First-In-Class Therapy for Cerebral Cavernous Malformations

  NEW YORK, July 01, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company dedicated to improving the lives of people affected by rare epilepsies and brain conditions, and Graviton Bioscience Corporation, a privately held clinical-stage biotechnology company focused on developing Rho-associated coiled-coil containing protein kinase 2 (ROCK2) inhibitors and other innovative therapeutic compounds, today announced the results from their Phase 1 healthy volunteer study evaluating the safety, tolerability, and pharmacokinetic (PK) profile of multiple ascending doses of OV888/GV101 capsule. Ovid and Graviton plan to progress to a Phase 2 clinical study in cerebral cavernous malformations (CCM) later this year.

  GlobeNewswire Inc.
• Wall Street Breakfast: The Week Ahead

  Stay up to date on Wall Street news with our daily podcast available on Seeking Alpha, iTunes, and Spotify.

  Seeking Alpha

  Featured Companies: APDN DJT FLYE GAUZ GRND INSM LIF MSM PSNY RAPP SLP SPCE STTK STZ TSLA UTHR WAY